Home Featured Page 55

Featured

Latest

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Psychedelic Literacy for Veterans: Bridging the Knowledge Gap in PTSD Recovery

Why Psychedelic Research is Booming: Current Trends and Hurdles

Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and...

Ketamine-Assisted Therapy at Work? The Future of Employee Benefits

Psychedelics on the Ballot 2024

Psychedelics Advocates Urge Yes on Question 4 Amid Last-Minute Debates

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future...

Psychedelics Lately – Massachusetts’ Question 4 and Updates in Psychedelics and...

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD...

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Psychedelic Literacy for Veterans: Bridging the Knowledge Gap in PTSD Recovery

Why Psychedelic Research is Booming: Current Trends and Hurdles

Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and...

Ketamine-Assisted Therapy at Work? The Future of Employee Benefits

Psychedelics on the Ballot 2024

Psychedelics Advocates Urge Yes on Question 4 Amid Last-Minute Debates

Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future...

Psychedelics Lately – Massachusetts’ Question 4 and Updates in Psychedelics and...

Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD...

OP-Ed: From a Massachusetts Psychiatrist: Why Doctors Support Yes on Question...

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY